Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 597 results
Filters: Author is Daar, Eric S  [Clear All Filters]
Found 597 results.

Adenine

Sax PE, Tierney C, Collier AC, et al. "Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results." J. Infect. Dis.. 2011;204(8):1191-201.
Andrade A, Rosenkranz SL, Cillo AR, et al. "Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248." J. Infect. Dis.. 2013;208(6):884-91.
McComsey GA, Daar ES, O'Riordan MA, et al. "Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202." J. Infect. Dis.. 2013;207(4):604-11.
Sax PE, Tierney C, Collier AC, et al. "Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy." N. Engl. J. Med.. 2009;361(23):2230-40.
Wyatt CM, Kitch D, Gupta SK, et al. "Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine." J. Acquir. Immune Defic. Syndr.. 2014;67(1):36-44.
Hogan CM, Degruttola V, Sun X, et al. "The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals." J. Infect. Dis.. 2012;205(1):87-96.
Grant PM, Tierney C, Budhathoki C, et al. "Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202." HIV Clin Trials. 2013;14(6):284-91.
McComsey GA, Kitch D, Daar ES, et al. "Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG." J. Infect. Dis.. 2011;203(12):1791-801.
McComsey GA, Kitch D, Daar ES, et al. "Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir." AIDS. 2012;26(11):1371-85.

Pages